Alzheimer's Disease is a neurodegenerative disease where the build-up of the proteins amyloid and tau damage the nerve cells in the brain. A progressive disorder, Alzheimer’s develops over time with symptoms increasing in severity.
Between 60–80% of dementia cases are caused by Alzheimer's disease. Rapid diagnosis is important, as treatment early in the course of AD helps maintain cognitive and functional performance and delay the emergence of distressing behavioural and psychological symptoms, such as depression, anxiety and apathy.
Cholinesterase inhibitors can be used alone or in combination to manage the behavioural and psychological symptoms of Alzheimer's disease. However current treatments do not cure Alzheimer's disease and functional and cognitive decline are inevitable.
To find out more about Alzheimer's Disease visit our dedicated Learning Zone, which contains expert-led information on diagnosing behavioural and psychological symptoms, and the treatment options available.
Latest Clinical Guidelines, Trials and Journals
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics...
These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG.
Latest news and insights
Epizyme announced that the FDA has accepted for filing the company's New Drug Application (NDA) for the accelerated approval of Tazverik (tazemetostat) for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy.
Bristol-Myers Squibb announced that the FDA has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel), the company's autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy
Biotronik has announced CE Mark certification for the Orsiro Mission drug-eluting stent (DES) system. The next generation of the company's ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents. Orsiro Mission is now available in CE Mark countries.